DBV Technologies (Euronext: DBV; ISIN: FR0010417345; NASDAQ: DBVT) has announced that three presentations at the American College of Allergy, Asthma & Immunology (ACAAI) 2026 Annual Scientific Meeting in Phoenix, Arizona, featured new data from its Phase 3 VITESSE clinical trial of the VIASKIN Peanut Patch in peanut-allergic children aged four to seven years.
According to DBV, the presentations examined changes in allergic reaction severity during double-blind, placebo-controlled food challenges, the potential practicality of the VIASKIN Peanut Patch treatment using epicutaneous immunotherapy, and changes to immunologic biomarkers during the 12-month VITESSE study.
VITESSE, the largest food allergy immunotherapy trial to date, randomized 654 children 2:1 to receive the VIASKIN Peanut Patch containing 250 µg of peanut protein or placebo for 12 months. The study met its primary endpoint, with 46.6% of children in the VIASKIN Peanut Patch arm meeting treatment responder criteria at month 12, compared with 14.8% in the placebo arm (difference in response rates = 31.8%; 95% confidence interval [CI]: 24.5%, 39.0%; p < 0.001).
In a statement, Pharis Mohideen, MD, chief medical officer of DBV, commented, “The VITESSE data presented at ACAAI add important context to the study’s overall positive results. After one year of treatment, children receiving the VIASKIN Peanut Patch in the study had statistically significantly lower maximum symptom severity during food challenge, along with immunologic changes consistent with other forms of allergen immunotherapy. I am also pleased that the practicality data show high treatment compliance in young children with common atopic comorbidities, and that all participants were able to continue their typical daily activities, including bathing, sports, and swimming, while on treatment.”
